About this opportunity
Karyopharm Therapeutics Inc. lists this Medical Science Liaison (MSL) - Southwest opportunity in northern, Kentucky. Review the employer’s description below for duties, qualifications and application requirements.
Job description
Role Overview & Key Functions:
The Medical Science Liaison (MSL) is responsible for the identification and engagement of a targeted group of national and regional thought leaders/healthcare professionals (HCPs), as well as payers and managed care accounts. This position provides consistent delivery of educational and compliant scientific information in support of Karyopharm’s pipeline.
Identify and develop relationships with community/academic thought leaders along with treatment advocates on a local, regional, and national level.
Serve as Karyopharm’s scientific representative to the medical community and facilitate the appropriate exchange of scientific information.
Provide clinical and economic value information to payers and formulary decision makers.
Utilize approved resources to address customer needs, ensuring they are in compliance with all guidelines and regulations.
In partnership with clinical operations, support trial awareness, enrollment, and identification of potential sites/investigators for clinical trial participation.
Serve as the key liaison for all aspects of investigator sponsored research.
Communicate therapeutic market trends which may impact Karyopharm’s pipeline.
Participate and support advisory boards and steering committees.
Lead and/or participate on committee/project teams which support MSL strategies as delegated by MSL leadership
Gain feedback through field interactions with HCPs to uncover collaboration opportunities and pair customer’s unmet needs with available internal resources.
The candidate will assume a leadership role by teaching, coaching and mentoring new hires and/or less experienced MSLs and by assuming responsibility for special projects as they arise.
At Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $180 K - $220 K USD.
Candidate Profile & Requirements:
Advanced doctoral degree preferred (e.g. PharmD, MD, DO, or PhD). Candidates with a clinical background (e.g. MSN, PA) and extensive hematology/oncology MSL experience will be considered.
1+ years’ MSL experience in oncology strongly preferred; experience in multiple myeloma preferred.
Product launch experience a plus.
Clinical experience beneficial.
Exceptional interpersonal skills.
Ability to excel in dynamic settings with short timelines.
Strong written/verbal communication and presentation skills.
Ability to establish and maintain relationships with influential thought leaders.
Thorough understanding of FDA, OIG, HIPAA and other ethical guidelines, laws, and regulations relevant to the pharmaceutical industry.
Valid driver’s license and the ability to travel as necessary (up to 75% including some weekends).
Our Value Proposition:
This is a uniquely exciting time to joinKaryopharm Therapeuticswhere we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer.We are building upon an established commercial foundation in multiple myeloma while advancing the potential ofselinexoracrossadditionalhematologic and solid tumorcancersincludingmyelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs.
Our lead therapy, XPOVIO®(selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S.We are also exploring opportunities to evaluate XPO1 inhibitionacross myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generationcompounds, includingeltanexor.
As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued.
Learn more at Karyopharm Therapeutics.
#J-18808-Ljbffr
Who can apply
Review the original listing for work authorization, qualifications and employer requirements.